LWBK1006-Index LWW-Govindan-Review December 19, 2011 19:14
600 Indexcore biopsy for, 333, 342
detection, breast sonography for,
167, 179–180
diagnosis of, 333, 342
estrogen and progestin, 332,
341–342
exemestane in, 338, 346
fulvestrant in, 338, 346
Gail model in, 333, 342
germ line mutations and, 331,
341
HER2+, 337, 346
Her2/neu amplification in, 4, 11
Hodgkin’s lymphoma and, 143,
147
isolated axillary adenopathy, 480
ixabepilone to capecitabine
addition in, 338, 346
lapatinib to capecitabine addition
in, 337, 346
LCIS and, 143, 147
Li-Fraumeni syndrome and, 332,
341
locally advanced, 339, 347
male, 339, 347
staging and treatment of, 339,
347
mammographic breast density,
332, 342
mammography of, 340, 348
MRI of, 168, 180
MR screening of, 332, 342
MSCC and, 506
neoadjuvant chemotherapy in,
339, 347
OncotypeDX assay, 336, 345
oophorectomy in, 333, 342
paclitaxel, 337, 346
radiation exposure, 332, 341
raloxifene in, 342
risk factors for, 332, 341, 342
screening, mammography for,
167, 179
soy products consumption and,
62, 68
staging, 167, 180
surgical biopsy of, 333, 342
and SVC syndrome, 506
tamoxifen for, 336, 342, 345
T2N1M0, 334, 343
trastuzumab for, 337, 345
treatment, pregnancy and, 338,
347
types of, 334, 343
Breast conserving surgery (BCS),
334
Breast self-examination (BSE), 144,
147
Breast sonography, 167, 179–180British National Lymphoma
Investigation (BNLI), 426
Broadspectrum antibiotics, in
anorectal infections, 542,
547–548
Bromhexine, 577
Bronchoscopy, of neuroendocrine
carcinomas, 479
BSE.SeeBreast self-examination
(BSE)
BSO.SeeBilateral salpingo-
oophorectomy (BSO)
Bupropion, mechanism of, 136, 138
Burkitt’s lymphoma, 50, 264, 268,
498, 501
classic translocations in, 413, 428
EBV expression in, 52, 106, 111
Busulfan, 441, 447, 531
VOD and, 531, 532CA 19-9 and pancreatic cancer,
243, 247
Cabazitaxel, 124, 130
Cachexia, metabolic abnormalities
in, 565, 570
Cadmium, prostate cancer and, 57,
63
CAF.SeeCancer-associated stromal
fibroblasts (CAF)
Calcitonin
for hypercalcemia, 361
for reduction in calcium level, 508
CALGB.SeeCancer and Leukemia
Group B (CALGB)
cAMP.SeeCyclic adenosine
monophosphate (cAMP)
Cancer
age and, 70, 74–75
antiangiogenic therapy for, 28
of anus
treatment, chemoradiation with
5FU and mitomycin in,
272, 276
bevacizumab in, 28
of bladder
aromatic amines and, 33, 43
BCG in, 281, 289–290
cisplatin-based multiagent
chemotherapy in, 281, 290
PTEN and, 281, 289
RB1 and, 281, 289
risk factor for, 285, 293
Schistosoma haematobiumand,
285, 293
TP53 and, 281, 289
of breast
ADH and, 143, 147
alcohol consumption and, 61,
67anastrazole in, 338, 346
aromatase inhibitor therapy in,
133
ataxia-telangiectasia and, 60, 65
bevacizumab, 337, 346
BRCA1 and, 35, 46, 305, 311,
328, 331, 341
BRCA2 and, 152, 158
causes of, 331, 341
chemotherapy for, 337, 346
core biopsy for, 333, 342
detection, breast sonography
for, 167, 179–180
diagnosis of, 333, 342
estrogen and progestin, 332,
341–342
exemestane in, 338, 346
fulvestrant in, 338, 346
Gail model in, 333, 342
germ line mutations and, 331,
341
HER2+, 337, 346
Her2/neu amplification in, 4, 11
Hodgkin’s lymphoma and, 143,
147
ixabepilone to capecitabine
addition in, 338, 346
lapatinib to capecitabine
addition in, 337, 346
LCIS and, 143, 147
Li-Fraumeni syndrome and,
332, 341
locally advanced, 339, 347
male, 339, 347
mammographic breast density,
332, 342
mammography of, 340, 348
MRI of, 168, 180
MR screening of, 332, 342
neoadjuvant chemotherapy in,
339, 347
OncotypeDX assay, 336, 345
oophorectomy in, 333, 342
paclitaxel, 337, 346
radiation exposure, 332, 341
raloxifene in, 342
risk factors for, 332, 341, 342
screening, mammography for,
167, 179
soy products consumption and,
62, 68
staging, 167, 180
surgical biopsy of, 333, 342
tamoxifen for, 336, 342, 345
T2N1M0, 334, 343
trastuzumab for, 337, 345
treatment, pregnancy and, 338,
347
types of, 334, 343